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ABSTRACT
We evaluated the association of mutations in 34 candidate genes and response 
to azacitidine in 84 patients with myelodysplastic syndrome (MDS), with 217 somatic 
mutations identified by next-generation sequencing. Most patients (93%) had ≥1 
mutation (mean=2.6/patient). The overall response rate to azacitidine was 42%. 
No clinical characteristic was associated with response to azacitidine. However, total 
number of mutations/patient was negatively associated with overall drug response 
(odds ratio [OR]: 0.56, 95% confidence interval [CI]: 0.33–0.94; p=0.028), and a 
positive association was found for having ≥1 mutation in a DNA methylation-related 
gene: TET2, DNMT3A, IDH1 and/or IDH2 (OR: 4.76, 95%CI: 1.31–17.27; p=0.017). 
Mutations in TP53 (hazard ratio [HR]: 3.88; 95%CI: 1.94–7.75) and EZH2 (HR: 2.50; 
95%CI: 1.23–5.09) were associated with shorter overall survival. Meta-analysis of 
6 studies plus present data (n=815 patients) allowed assessment of the association 
of drug response with mutations in 9 candidate genes: ASXL1, CBL, EZH2, SF3B1, 
SRSF2, TET2, DNMT3A, IDH1/2 and TP53. TET2 mutations predicted a more favorable 
drug response compared with ‘wild-type’ peers (pooled OR: 1.67, 95%CI: 1.14–2.44; 
p=0.01). In conclusion, mutations in the DNA methylation pathway, especially TET2 
mutations, and low number of total mutations are associated with a better response 
to azacitidine.
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INTRODUCTION
Myelodysplastic syndrome (MDS) comprises a 
heterogeneous group of clinical entities characterized by 
hematopoietic stem cell damage, leading to peripheral 
cytopenia and high risk for progression to acute leukemia. 
At present, the hypomethylating agents azacitidine and 
decitabine are the only approved drugs for treatment 
of MDS; however, only 40–50% of patients respond to 
therapy, although there is individual variability [1]. It is 
thus important to identify biomarkers that can predict 
individual treatment response.
Alterations in DNA methylation are involved in the 
pathogenesis of MDS. Patients show aberrant methylation 
of cytosine residues in CpG sequences [2, 3] and a DNA 
hypermethylation profile, particularly in promoter regions 
of tumor suppressor genes [4, 5]. These genetic alterations 
can impact patients’ survival [6–10], yet whether they can 
also influence their response to azacitidine/decitabine 
treatment has not been clearly elucidated.
DNA methylation status or mutations in genes 
involved in DNA methylation (e.g., those encoding cyclin 
dependent kinase inhibitor 2B [CDKN2B], estrogen 
receptor 1 [ESR1], immunoglobulin superfamily member 
4 [IGSF4] or Tet methylcytosine dioxygenase [TET2]) 
are candidates to influence the response to treatment with 
hypomethylating drugs in MDS [1, 11–13], but there is no 
unanimity between studies and some data do not support 
such associations [14–18]. Mutated clone size, mutations 
in different genes of the same pathway, or interactions 
between gene mutations, could also affect the response 
rate to hypomethylating agents and explain, at least in 
part, heterogeneity between studies as well as individual 
variability in treatment response.
The main purpose of our study was to evaluate 
the impact of gene mutations that are candidates to 
be involved in MDS pathogenesis, detected by next-
generation sequencing (NGS), on the response to 
azacitidine treatment in a cohort of MDS patients. We also 
performed a meta-analysis, pooling our data with those of 
available studies, to systematically assess the impact of 
mutational status on such response.
RESULTS
Main clinical characteristics
The demographic and clinical characteristics of the 
84 patients are detailed in Table 1. The median follow-
up and time from diagnosis to azacitidine treatment was 
17 (range 1–93) and 2 months (range 0–22), respectively. 
Low and intermediate risk patients were treated because 
of severe cytopenias or excess of blasts. Patients 
received a median number of 6 cycles of treatment with 
azacitidine (range 1–55). Fifteen patients with less than 
4 cycles of therapy were evaluated as unresponsive due 
to progression of the disease. At the time of analysis, 29 
patients (35%) were continuing on azacitidine therapy. 
The remaining patients had previously interrupted 
treatment due to toxicity, progression, or allogeneic stem 
cell transplantation (one case).
Profile of somatic mutations in MDS patients
We analyzed frequently mutated regions in 34 genes 
that are candidates to be involved in the pathogenesis of 
MDS (i.e., with a function in DNA methylation, RNA 
splicing, histone modulation pathways, or synthesis of 
transcription/signaling factors).
A total of 217 single nucleotide variants (SNVs) 
and/or deletions/insertions (indels) were identified by 
NGS in 78 of 84 patients (93%) (Supplementary Table 
1). On average, 2.6 variants (range 0–6) were found 
per patient. The most frequent mutations (each present, 
alone or in combination, in ≥10% of patients) were found 
in the following genes: TET2 (27%); tumor protein p53 
(TP53, 20%); DNA methyltransferase 3 alpha (DNMT3A, 
19%); runt-related transcription factor 1 (RUNX1, 18%); 
enhancer of zeste 2 polycomb repressive complex 2 
subunit (EZH2, 14%); additional sex combs like 1, 
transcriptional regulator (ASXL1, 13%); U2 small nuclear 
RNA auxiliary factor 1 (U2AF1, 12%); splicing factor 
3b subunit 1 (SF3B1, 11%); and zinc finger CCCH-type, 
RNA binding motif and serine/arginine rich 2 (ZRSR2, 
10%).
The frequencies of these mutations were similar 
to those published previously [19–21]. Nevertheless, we 
found a lower frequency of SF3B1 mutations, associated 
with good prognosis, and a higher frequency of poor 
prognosis mutations (TP53, RUNX1, EZH2, U2AF1, 
NRAS). This can be explained by the fact that our series of 
patients are characterized by therapy requirements, and a 
high proportion of high-risk patients are included.
Response to azacitidine and its association with 
genetic factors
Overall response to azacitidine was 42%, 
including complete (17%) or partial (5%) remission, and 
hematologic improvement (20%). In univariate analysis, 
the overall response rate was significantly and positively 
associated with the number of azacitidine cycles (odds 
ratio [OR]=1.17; 95% confidence interval [CI]: 1.11–1.30; 
p=0.003), but significantly and negatively associated with 
the total number of mutations (irrespective of the gene/s) 
per patient (OR=0.64; 95%CI: 0.44–0.94; p=0.022). Both 
parameters (number of azacitidine cycles and number of 
mutations) differed between responder and non-responder 
patients (Table 2).
When considering only those genes involved 
in DNA methylation [TET2, DNMT3A, isocitrate 
dehydrogenase 1 (IDH1) and 2 (IDH2)], or in chromatin 
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Table 1: Clinical characteristics of patients (n=84)
Gender Male/Female 30/54
Age (years) Median (range) 69 (49–99)
Hemoglobin (g/dL)  
 ≥10 31 (39%)
 8–9.9 33 (41%)
 <8 16 (20%)
Platelets (x109/L)  
 ≥100 29 (36%)
 50–99 22 (27%)
 <50 30 (37%)
Leukocytes (x109/L)  
 ≥1.5 76 (95%)
 <1.5 4 (5%)
WHO classification (n (%))  
 RA 1 (1%)
 RCMD 18 (22%)
 RAEB1 21 (25%)
 RAEB2 19 (23%)
 5q- 2 (2%)
 CMML 7 (8%)
 MDS-U 5 (6%)
 MDS/AML 11 (13%)
Cytogenetic risk  
 Very good 2 (2%)
 Good 41 (49%)
 Intermediate 13 (16%)
 Poor 10 (12%)
 Very poor 18 (21%)
IPSS-R category  
 Very low 2 (2%)
 Low 15 (18%)
 Intermediate 20 (24%)
 High 23 (27%)
 Very high 21 (25%)
 Unclassified 3 (4%)
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; IPSS-R, Revised International 
Prognostic Score System; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB, refractory anemia with 
excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; 5q-, MDS with isolated 5q deletion; MDS-U: 
myelodysplastic syndrome unclassified; WHO, World Health Organization.
Oncotarget106951www.impactjournals.com/oncotarget
modification (ASXL1, EZH2), we found that both the 
presence of ≥1 mutation in DNA methylation genes 
(OR=3.53; 95%CI: 1.10–12.38; p=0.048) and the 
number of mutations in the DNA methylation pathway 
group (OR=2.37; 95%CI: 1.10–5.36; p=0.038) were 
positively and significantly associated with complete 
response. No such association was found with mutated 
genes involved in chromatin modification pathways 
(Table 3).
In multivariate analysis, the overall response 
rate remained positively associated with the number of 
azacitidine cycles (OR=1.19; 95%CI: 1.05–1.35; p=0.006) 
and with the presence of ≥1 mutation in genes related to 
DNA methylation pathways (OR=4.76; 95%CI: 1.31–
17.27; p=0.017), but negatively so with the total number 
of mutations per patient (OR=0.56; 95%CI: 0.33–0.94; 
p=0.028) (Table 3).
Because TET2 has shown association with 
azacitidine response in previous studies [1, 12–13], we 
analyzed the influence of the other genes related to the 
DNA methylation pathway. When we considered only the 
cohort of patients with TET2 wild-type, the multivariate 
Table 2: Comparison between responder and non-responder patients
 Responders N=35 Non-responders N=49 P-value*
Gender    
 Male/Female 22/13 32/17 0.817
Age (years)    
 Mean± SD 68±8 67±9 0.589
Hemoglobin (g/dl)    
 Mean± SD 9.6±1.4 9.4±2.0 0.628
Platelets (x109/L)    
 Mean± SD 125.2±140.5 90.9±92.4 0.189
Leukocytes (x109/L)    
 Mean± SD 6.9±9.1 6.2±8.3 0.725
BM blast (%)    
 Mean± SD 9.6±9.4 9.3±8.9 0.860
WHO classification    
 RCUD, RCMD, CMML, 5q- 10/35 (29%) 18/49 (37%) 0.434
 RAEB, AML 25/35 (71%) 31/49 (63%)  
Cytogenetic risk    
 Very good, good, intermediate 24/35 (69%) 32/49 (65%) 0.754
 Poor, very poor 11/35 (31%) 17/49 (35%)  
IPSS-R    
 Very low, low, intermediate 17/35 (49%) 20/49 (41%) 0.480
 High, very high 18/35 (51%) 29/49 (59%)  
Number of azacitidine cycles    
 Mean± SD 12.91±11.76 6.16±4.03 <0.001
Number of mutations per patient    
 ≤2 mutations 27/35 (77%) 27/49 (55%) 0.038
 >2 mutations 8/35 (23%) 22/49 (45%)  
*P- value: Chi square test was used in categorical variables, and Student´s t-test was used for continuous variables. 
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CMML, chronic myelomonocytic leukemia; IPSS-R, 
Revised International Prognostic Score System; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB, 
refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; 5q-, MDS with isolated 5q 
deletion; WHO, World Health Organization.
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analysis found the same significant variables associated 
with better response: number of azacitidine cycles (OR: 
1.14; 95%CI: 1.01–1.28; p=0.035), number of mutations 
(OR: 0.44; 95%CI: 0.21–0.89; p=0.023), and mutations 
in DNA methylation-related genes (considering only 
DNMT3A, IDH1 and IDH2) (OR: 5.80; 95%CI: 1.10–
30.85; p=0.039).
The following scoring model was designed using 
molecular variables at diagnosis: (group 1) total number 
of mutations per patient ≤2 and at least ≥1 mutation 
per patient in DNA methylation pathway; (group 2) 
total number of mutations per patient >2 and at least 
≥1 mutation per patient in DNA methylation pathway; 
(group 3) total number of mutations per patient ≤2 and 
0 mutations per patient in DNA methylation genes; 
and (group 4) total number of mutations per patient 
>2 and 0 mutations per patient in DNA methylation 
pathway (Figure 1). The proportion of responders to 
azacitidine differed across the aforementioned four 
groups: 67% (12/18) for group 1, 33% (7/21) for group 
2, 46% (15/33) for group 3, and 8% (1/12) for group 4 
(p=0.012). Significant differences were found between 
group 1 (higher rate of response than expected, 68%) 
and group 4 (lower rate of response than expected, 8%) 
(OR=0.36; 95%CI: 0.17–0.76; p=0.008). The following 
two variables, mutation number and the presence or 
absence of mutations in DNA methylation-related 
genes, contributed to these differences. Indeed, group 
1 presented a significant higher probability of response 
than patients with more than 2 mutations (groups 2 and 
4) (OR=0.16; 95%CI: 0.05–0.57; p=0.004), but also 
than patients with 0 mutations in DNA methylation 
pathway (groups 3 and 4) (OR=0.28; 95%CI: 0.09–0.88; 
p=0.029).
Clinical and genetic predictors of survival
In univariate analysis, considering clinical variables, 
median of overall survival was significantly higher in the 
group with platelet count above 100×109/L (p=0.001), 
low-risk patients according to WHO classification 
(p=0.014), good cytogenetic risk patients (p=0.016), 
very low/ low/intermediate IPSS-R (revised international 
prognostic score system) groups (p=0.007) and responders 
to azacitidine (p=0.031). Regarding mutations in the 34 
studied genes, we found a significant negative association 
with overall survival for the presence of mutations in 
either TP53 (p=0.001) or RUNX1 (p=0.019), as well as 
a non-significant trend for the presence of mutations in 
EZH2 (p=0.062) (Table 4).
We further analyzed whether the presence of >2 
mutations (i.e., above the mean number of mutations per 
patient in our cohort, 2.6) influenced survival, finding that, 
irrespective of the gene in question, having >2 mutations 
was associated with a shorter survival as compared with 
having ≤2 mutations (p=0.002) (Table 4).
In multivariate analysis, having ≥1 mutation in TP53 
[hazard ratio (HR)=3.88; 95CI%: 1.94–7.75; p<0.001] or 
EZH2 remained the most important prognostic factor for 
overall survival (HR=2.50; 95%CI: 1.23–5.09; p=0.012). 
Interestingly, the impact of mutational status of TP53 and 
EZH2 in overall survival was independent of the response 
to azacitidine (Figure 2).
Meta-analysis results
The results from 6 previous studies [1, 12, 13, 17, 
22, 23] and the present data, involving a total of 815 
patients with mutation analysis in at least one of the 9 
candidate genes studied, were pooled in the meta-analysis, 
allowing us to assess the association of drug response with 
mutations in 9 genes [ASXL1, Cbl proto-oncogene (CBL), 
DNMT3A, EZH2, IDH1/IDH2, SF3B1, serine and arginine 
rich splicing factor 2 (SRSF2), TET2 and TP53] (Figure 
3). All 7 studies were of high quality according to the 
Newcastle-Ottawa scale.
The combined response rate of patients (22% of 
total) with ≥1 TET2 mutation was 56% (95%CI: 42%–
69%), with significant heterogeneity among studies 
(I2=60.3%, Q=12.6) and no evidence of publication 
bias (p=0.937) (Figure 4). Such combined response was 
significantly higher (p<0.01) than that of the remaining 
patients harboring no TET2 mutation (43%) (95%CI: 
35%–52%), with significant heterogeneity among studies 
(I2=77.4%, Q=22.1) and no evidence of publication bias 
(p=0.4) (Figure 4). Combining the data on TET2 from the 
aforementioned studies with ours (total n=716 participants 
with available data of TET2 mutation status), the 
combined response rate to treatment was more favorable 
in those patients with ≥1 genetic mutation in TET2 than in 
those with no TET2 mutation (pooled OR=1.67, 95%CI: 
1.14–2.44, p=0.01) (Figure 4). There was no evidence 
of publication bias (p=0.94) or heterogeneity among the 
studies (I2=0.00%, Q=3.99).
No other significant association was found between 
gene mutations and treatment response (all p>0.1) 
(Supplementary File 2).
DISCUSSION
We have found that the profile of several gene 
mutations identified at diagnosis may represent a useful 
predictive biomarker of the response to azacitidine therapy 
in patients with MDS. Accordingly, patients with a total of 
≤2 somatic mutations in candidate genes and ≥1 mutation 
in genes of the DNA methylation pathway (TET2, 
DNMT3A, IDH1, and IDH2) had an overall response rate 
of 67%, which is well above the typical expected value 
(40–50%). By contrast, patients with >2 somatic mutations 
in total but having none in the aforementioned pathway 
represented the group with the lowest probability of 
response to treatment with azacitidine (8%). Meta-analysis 
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Table 3: Association of gene mutations with overall response to azacitidine
Univariate analysis
Mutated genes OR (CI 95%) P-value*
DNA methylation factors   
TET2 1.07 (0.39–2.90) 0.898
DNMT3A 1.78 (0.58–5.47) 0.316
IDH1 2.91 (0.25–33.41) 0.391
IDH2 3.03 (0.52–15.57) 0.216
Histone modulators   
ASXL1 0.48 (0.12–1.96) 0.307
EZH2 0.24 (0.05–1.16) 0.075
Splicing factors   
SF3B1 0.15 (0.02–1.27) 0.081
ZRSR2 0.43 (0.08–2.29) 0.326
U2AF1 2.33 (0.60–8.97) 0.219
Transcription factors   
TP53 0.72 (0.24–2.16) 0.552
RUNX1 0.45 (0.13–1.54) 0.201
ETV6 0.33 (0.04–3.10) 0.332
Signaling factors   
JAK2 3.03 (0.52–17.57) 0.216
CBL 2.20 (0.35–13.94) 0.401
RAS family   
KRAS 0.33 (0.04–3.10) 0.332
NRAS 0.21 (0.02–1.84) 0.159
Gene interactions   
TET2mut + ASXL1wt 0.98 (0.33–2.87) 0.963
TET2mut +ASXL1mut 1.42 (0.19–10.63) 0.730
TET2wt +ASXL1mut 0.21 (0.02–1.84) 0.159
DNMT3Amut + ASXL1wt 1.5 (0.47–4.75) 0.490
DNMT3Amut + ASXL1mut 2.33 1.000
DNMT3Awt + ASXL1mut 0.31 (0.06–1.56) 0.156
At least 1 mutation in DNA methylation genes 3.53 (1.10–12.38) 0.048**
Nº of mutations in DNA methylation genes 2.37 (1.10–5.36) 0.038**
Multivariate analysis
Significant variables OR (CI 95%) P-value*
Nº of cycles of azacitidine 1.19 (1.10-1.35) 0.006
At least 1 mutation in DNA methylation genes 4.76 (1.31-17.27) 0.017
Nº total of gene mutations 0.56 (0.33-0.94) 0.028
Abbreviations: CI: confidence interval; OR: odds ratio; mut: mutated; wt: wild-type.
*P-value logistic regression results.
** Association with complete response.
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revealed that the TET2 gene is the strongest biomarker of 
clinical response.
High-sensitivity sequencing of a specific panel of 
myeloid-related genes has allowed us to identify somatic 
mutations in >90% of the MDS patients we studied. The 
inclusion of molecular markers in prognostic scores for 
MDS, together with other clinical and genetic data, is 
likely to lead to a better prediction of patient outcomes 
in the near future. Previous studies have assessed the 
role of candidate gene mutations in the context of MDS 
therapy, including response to erythropoietic stimulating 
agents [24], to hypomethylating agents [1, 12, 13, 17, 22, 
23, 25, 26], or in the bone marrow transplantation setting 
[27–29]. In the present study, no clinical characteristic 
was associated with overall response to azacitidine, and 
the same was true for any single mutated gene. Yet, our 
Figure 1: Spectrum of mutations in the 84 patients with myelodysplastic syndrome (MDS) (where each row represents 
a single patient). Only 28 genes are shown, the remainder of genes analyzed did not present mutations in this cohort of patients (SF1, 
VHL, KDM6A, PTEN, HRAS, and EPOR). Yellow (group 1): total number of mutations per patient ≤2 and at least ≥1 mutation per patient 
in DNA methylation pathway; Green (group 2): total number of mutations per patient ≤2, and 0 mutations per patient in DNA methylation 
genes; Blue (group 3): total number of mutations per patient >2 and at least ≥1 mutation per patient in DNA methylation pathway; and Red 
(group 4): total number of mutations per patient >2, and 0 mutations per patient in DNA methylation pathway.
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results support the notion that the DNA methylation 
pathway is influential in the response to therapy in MDS. 
Some previous studies have found an association of TET2 
mutations with treatment response to azacitidine when 
the histone modifier ASXL1 was not mutated or when a 
mutated clone over 10% was considered [13], but other 
authors found no such association [17, 22]. When we 
considered all genes related to the DNA methylation 
pathway (TET2, DNMT3A, IDH1, and IDH2), the presence 
of mutation/s in any of them was related to overall 
treatment response. No additional prognostic values were 
found when we combined the aforementioned genes with 
other epigenetic genes, such as ASXL1.
A particularly interesting finding of our clinical 
study was that the total number of mutations in candidate 
genes per patient was inversely related to the response 
to azacitidine, with previous research showing a close 
relationship between survival, but not of response 
to this drug [20]. Although we have not performed a 
comprehensive mutational analysis (only 34 genes were 
studied), all genes with mutation frequencies above 2% 
in myelodysplastic syndromes according to the European 
Table 4: Prognostic factors for overall survival (univariate survival analysis using the Kaplan-Meier method)
Factors Overall survival Median (months) (95%CI) P- value*
Platelets (x109/L)   
 ≥100 34 (16–52) 0.001
 50-99 23 (13–33)  
 <50 16 (7–25)  
WHO classification   
 RCUD, RCMD, CMML, 5q- 34 (20–48) 0.014
 RAEB, AML 18 (16–20)  
Cytogenetic risk   
 Very good, good, intermediate 24 (17–31) 0.016
 Poor, very poor 17 (12–23)  
IPSS-R   
 Very low, low, intermediate 29 (21–37) 0.007
 High, very high 18 (16–20)  
Response to azacitidine   
 Responders 29 (21–37) 0.023
 Non-responders 17 (14–20)  
TP53   
 Unmutated 25 (18–32) 0.001
 Mutated 11 (7–14)  
RUNX1   
 Unmutated 24 (17–32) 0.019
 Mutated 18 (17–19)  
EZH2   
 Unmutated 23 (21–26) 0.062
 Mutated 17 (11–23)  
Nº of mutations per patient   
 ≤2 26 (14–37) 0.002
 >2 17 (12–22)  
*for Kaplan–Meier (log rank) test results.
Oncotarget106956www.impactjournals.com/oncotarget
Figure 2: Overall survival for responder and non-responder patients depending on EZH2 and/or TP53 mutational 
status. Median overall survival of 35 months versus 17 months (in TP53 and EZH2 wild-type versus TP53 and/or EZH2 mutated patients, 
respectively) in responders to azacitidine (log rank statistic p=0.017). Median overall survival of 23 months versus 11 months (in TP53 and 
EZH2 wild-type versus mutated patients) in non-responders to azacitidine (log rank statistic p=0.007).
Figure 3: Flow chart of studies included and excluded in the meta-analysis. Fifty papers were identified in the electronic 
databases PubMed, Embase, Cochrane library and Web of Science. Revisions and studies with no genetic information or no hypomethylating 
therapy were excluded. Finally, seven studies (including current data) containing mutational status of 9 genes were included in the meta-
analysis.
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LeukemiaNet recommendations were included [30]. 
Moreover, the association we found between higher total 
number of mutations per patient and lower response rate 
to azacitidine remained after adjusting for IPSS-R. The 
molecular complexity of the disease both at diagnosis 
and during its progression can determine the probability 
of response to therapy. Further, we hypothesize that 
acquisition of additional mutations could be one of the 
reasons for loss of treatment response, which should be 
explored in future research. Those patients with a total of 
>2 somatic mutations but none in the DNA methylation 
pathway had the lowest probability to respond to 
azacitidine (i.e., of only 8%). Thus, alternative therapies 
should be considered in this group of poor responders due 
to the low probability of successful therapy with this drug.
Searching for prognostic factors of survival, we 
based our analysis on clinical and molecular data. In 
this regard, we found two genes, TP53 and EZH2, with 
Figure 4: Results of meta-analysis for TET2. Combined response rate for patients with TET2 mutated (response rate: 56%; 95%CI: 
42–69%) resulted significantly higher than that of the remaining patients with TET2 wild-type (RR: 43%; 95%CI: 35–52%). The pooled 
odds ratio of response was favourable to TET2 mutations (pooled OR=1.67, 95%CI: 1.14–2.44, p=0.01). Abbreviations: OR, odds ratio: 
RR, response rate; WT, wild-type.
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a negative impact on overall survival, with this effect 
remaining after adjusting for IPSS-R risk. Both genes 
have been previously studied in high-risk MDS [19–21], 
but no association was reported with the response rate 
to therapy. Other authors have also described a negative 
influence of TP53 mutations in the survival patients with 
MDS or acute myeloid leukemia (AML), despite no 
effect on the response rate to azacitidine therapy [26, 31, 
32]. A study by Welch and colleagues [23] found higher 
response rates among patients with TP53 mutations than 
those among patients with wild-type TP53; although 77% 
of the patients were diagnosed with AML and not MDS, 
and the treatment regimen, 10-day course of decitabine, 
is unusual for MDS. Thus, whereas previously available 
and present data support treatment with hypomethylating 
agents in patients with TP53 and/or EZH2 mutations, their 
expected low survival rate advocates the need to explore 
other treatment strategies in this group of patients.
An additional strength and novelty of our study is 
the systematic review of the literature and subsequent 
meta-analysis, allowing us to confirm the significant role 
of TET2 mutations in response to azacitidine. Despite the 
heterogeneity among studies, the high number of patients 
in each group (mutated and ‘wild-type’ patients by each 
gene analyzed) supports the validity and generalizability 
of our meta-analysis.
In conclusion, a low total number of mutations in 
candidate genes coupled with one or more mutations in 
DNA methylation-related genes predict a better response 
to azacitidine. Furthermore, meta-analysis identified 
the TET2 gene as the strongest biomarker of treatment 
success. Mutational profiling of candidate genes provides 
important prognostic information for MDS patients 
under therapy. The presence of mutations in the DNA 
methylation pathway and the number of driver mutations 
are predictors of response to hypomethylating agents. 





A total of 84 patients with MDS from three Spanish 
institutions who had been (or were still) receiving 
azacitidine were included in the analysis. Bone marrow 
samples were obtained from patients at diagnosis and 
processed following standard work-up protocols. All 
patients gave their written informed consent to biobank 
samples. The following clinical characteristics were 
considered: gender, age, World Health Organization 
(WHO) classification, cytogenetic risk, IPSS-R, response 
to azacitidine (according to International Working group 
response criteria) [33] and outcome. Duration of follow-
up was censored at the time of transplantation, and in the 
remaining patients until loss or death.
High sensitivity targeted sequencing and mutation 
analysis
DNA was extracted from bone marrow mononuclear 
cells. High-depth NGS was performed using an Ion 
Torrent ProtonTM sequencer (Life Technologies, Palo Alto, 
CA). In each procedure performed, the total number of 
reads was ~2 million, with an average depth of coverage 
over 2, 000 reads by amplicon, along with high uniformity 
for all fragments (91.6%). Data analyses were performed 
using Ion Reporter 4.4 software (Life Technologies), 
which identified SNVs and indels. We used Ion Reporter 
default parameters and filtered out variants with a total 
coverage <40 reads and an allelic coverage <10 reads. 
All variants reported had a variant allele frequency above 
4%. Variants with a minor allelic frequency >0.01 in the 
general population according to the Single Nucleotide 
Polymorphism database and/or 5000 Exome Sequencing 
Project were rejected as possible polymorphisms [34]. 
Variants were categorized according to cancer mutation 
databases and algorithms for computational prediction 
of functional impact of variants (see Supplementary 
Information and Supplementary Table 1 ): type 1; variants 
of known clinical significance, type 2: variants of potential 
clinical significance, and type 3: variants of unknown 
clinical significance.
Statistical analysis
Clinical characteristics of the patients were 
compared with the χ2 test (or Fisher´s test if ≥80% of the 
cells of the cross table had an expected frequency <5) for 
categorical variables, and Student’s t test for continuous 
variables (or its non-parametric equivalent if data did not 
follow a normal distribution). The association between 
clinical variables, including mutational status, and the 
response to azacitidine, was investigated using logistic 
regression. Cox proportional hazard models and Kaplan-
Meier curves were used to assess association of variables 
(clinical data and mutations) with patient overall survival. 
Statistical significance level was set at 0.05 and analyses 
were conducted with SPSS 21.0 software (SPSS Inc., 
Chicago, IL).
Pooled meta-analysis
Eligibility criteria, information sources and search 
strategy
Relevant papers were identified in the electronic 
databases PubMed, Embase, Cochrane library and Web of 
Science, using the following keywords (chosen according 
to the scientific literature): “myelodysplastic syndrome/s”, 
“mutation”, “hypomethylating”, as well as any possible 
combinations of these terms, up to February 20, 2017. The 
title and abstracts of the selected articles were reviewed to 
determine the potential eligibility for meta-analysis.
Oncotarget106959www.impactjournals.com/oncotarget
The criteria for including a study in the systematic 
review were the following: patients with diagnosis of 
MDS who were treated with one hypomethylating agent 
(either azacitidine or decitabine), assessment of mutational 
analysis with sequencing platforms and information on the 
response rate in ‘mutated’ versus ‘wild-type’ patients for 
genes that are candidates to be involved in MDS.
Data extraction and quality assessment
We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [35] (Supplementary File 1). We collected the 
following items from each study, if available: number of 
patients with gene mutation/s, number of patients with a 
‘wild-type’ genotype (i.e., 0 mutations), and response rate 
of these two types of patients. Two independent reviewers 
extracted the data. The Newcastle-Ottawa scale was used 
to assess the quality of each study included in the meta-
analysis.
Statistical analysis
A random effects model meta-analysis of 
proportions was used to estimate the ‘combined 
response rate’ (95% CI to the treatment of MDS with 
hypomethylating therapy). Group rates were transformed 
using the Freeman-Tukey double arc-sine method with a 
standard error and sample size. The pooled results were 
then back-transformed to give estimates and forest plots 
in the original scale and these were reported. The pooled 
OR (95%CI) of response to treatment if having ≥1 gene 
mutation as compared with having the wild-type genotype 
was estimated using a weighted random-effect model.
Egger’s regression test was employed to identify 
the presence of publication bias, and heterogeneity 
among studies was assessed using the Cochrane Q-test 
and the I2 index. The level of significance was set at 0.05 
and statistical analyses were performed using MIX Pro 
software version 2.0 [36].
The data discussed in this publication have been 
deposited in the NCBI Sequence Read Archive (SRA) [37] 
and are accessible through
(http://www.ncbi.nlm.nih.gov/sra/SRP102906).
Supplementary information is available at the 
Oncotarget web site.
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